Chronicle Journal: Finance

Kintor Starts China Trial of Combination Therapy for Liver Cancer

Suzhou Kintor Pharma was approved to start a China Phase I trial of its ALK-1 antibody in combination with Bristol-Myers Squibb's PD-1, nivolumab (Opdivo®), in patients with advanced hepatocellular carcinoma. The ALK-1 antibody is a fully human IgG2 neutralizing mAb that inhibits ALK-1/TGF-β signal transduction, interrupting tumor angiogenesis and changing the tumor microenvironment. In 2018, Kintor acquired an exclusive global license from Pfizer for the candidate in all oncological applications. More details.... Stock Symbol: (HK: 9939) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.